Shares of Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) rose 1% on Wednesday . The stock traded as high as $55.89 and last traded at $54.63. Approximately 310,440 shares were traded during mid-day trading, an increase of 64% from the average daily volume of 189,291 shares. The stock had previously closed at $54.10.
Gemini Therapeutics Stock Performance
The firm’s 50-day moving average is $59.66 and its two-hundred day moving average is $54.94. The stock has a market cap of $2.37 billion, a P/E ratio of -54.63 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Further Reading
- Five stocks we like better than Gemini Therapeutics
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- Stock Splits, Do They Really Impact Investors?
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- How to Use the MarketBeat Dividend Calculator
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
